{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:01:55Z","timestamp":1770940915939,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003006","name":"Eidgen\u00f6ssische Technische Hochschule Z\u00fcrich","doi-asserted-by":"publisher","award":["MedLabs Fellowship 2023"],"award-info":[{"award-number":["MedLabs Fellowship 2023"]}],"id":[{"id":"10.13039\/501100003006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Centers for Precision Oncology Foundation","award":["Research Grant"],"award-info":[{"award-number":["Research Grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"DOI":"10.1186\/s41824-026-00286-8","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:02:02Z","timestamp":1770937322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of urinary bladder activity from [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in patients with prostate cancer undergoing PSMA-ligand PET\/CT"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5649-0710","authenticated-orcid":false,"given":"Korbinian","family":"Krieger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Cumming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian Leigh","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel Oliver","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"286_CR12","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","volume":"48","author":"IL Alberts","year":"2021","unstructured":"Alberts IL, Seide SE, Mingels C et al (2021b) Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging 48:2978\u20132989","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"286_CR8","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.2967\/jnumed.120.257741","volume":"62","author":"I Alberts","year":"2021","unstructured":"Alberts I, Niklas-H\u00fcnermund J, Sachpekidis C et al (2021a) Combination of forced diuresis with additional late imaging in (68)Ga-PSMA-11 PET\/CT: effects on lesion visibility and Radiotracer uptake. J Nucl Med 62:1252\u20131257","journal-title":"J Nucl Med"},{"key":"286_CR13","doi-asserted-by":"crossref","unstructured":"Allach Y, Banda A, van Gemert W et al (2022) An explorative study of the incidental high renal excretion of [(18)F]PSMA-1007 for prostate cancer PET\/CT imaging. Cancers (Basel) 14","DOI":"10.3390\/cancers14092076"},{"key":"286_CR7","doi-asserted-by":"crossref","unstructured":"Bayerschmidt S, Uprimny C, Kroiss AS et al (2021) Comparison of early imaging and imaging 60 min Post-Injection after forced diuresis with Furosemide in the assessment of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET\/CT. Diagnostics (Basel) 11","DOI":"10.3390\/diagnostics11071191"},{"key":"286_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Sch\u00e4fer M, Bene\u0161ov\u00e1 M et al (2017) Preclinical evaluation of (18)F-PSMA-1007, a new prostate-Specific membrane antigen ligand for prostate cancer imaging. J Nucl Med 58:425\u2013431","journal-title":"J Nucl Med"},{"key":"286_CR4","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1007\/s00330-016-4308-4","volume":"26","author":"T Derlin","year":"2016","unstructured":"Derlin T, Weiberg D, von Klot C et al (2016) (68)Ga-PSMA I&T PET\/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol 26:4345\u20134353","journal-title":"Eur Radiol"},{"key":"286_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13550-022-00913-y","volume":"12","author":"ML Donswijk","year":"2022","unstructured":"Donswijk ML, Wondergem M, de Wit-van der Veen L et al (2022) Effects of Furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET\/CT: a single-centre retrospective study. EJNMMI Res 12:42","journal-title":"EJNMMI Res"},{"key":"286_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.semradonc.2025.05.004","volume":"35","author":"V Dragonetti","year":"2025","unstructured":"Dragonetti V, Colandrea M, Travaini L et al (2025) PSMA-PET guided radiotherapy in prostate cancer: A critical review of current applications and future directions. Semin Radiat Oncol 35:317\u2013324","journal-title":"Semin Radiat Oncol"},{"key":"286_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","volume":"44","author":"MT Freitag","year":"2017","unstructured":"Freitag MT, Radtke JP, Afshar-Oromieh A et al (2017) Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with MpMRI integrated in simultaneous PET\/MRI. Eur J Nucl Med Mol Imaging 44:776\u2013787","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"286_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J et al (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678\u2013688","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"286_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13550-025-01271-1","volume":"15","author":"AI Khalimon","year":"2025","unstructured":"Khalimon AI, Nikiforuk AI, Khodzhibekova MM et al (2025) The impact of patient hydration and forced diuresis on [(18)F]PSMA-1007 urinary bladder uptake in PET\/CT imaging. EJNMMI Res 15:73","journal-title":"EJNMMI Res"},{"key":"286_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.123.266527","volume":"65","author":"A Light","year":"2024","unstructured":"Light A, Lazic S, Houghton K et al (2024) Diagnostic performance of (68)Ga-PSMA-11 PET\/CT versus multiparametric MRI for detection of intraprostatic radiorecurrent prostate cancer. J Nucl Med 65:379\u2013385","journal-title":"J Nucl Med"},{"key":"286_CR21","doi-asserted-by":"publisher","unstructured":"Orevi M, Simona BH, Galith A et al (2022) False positive findings of [18F]PSMA-1007 PET\/CT in patients after radical prostatectomy with undetectable serum PSA Levels. Front Surg 9 https:\/\/doi.org\/10.3389\/fsurg.2022.943760","DOI":"10.3389\/fsurg.2022.943760"},{"key":"286_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13550-020-0593-7","volume":"10","author":"S Piron","year":"2020","unstructured":"Piron S, De Man K, Schelfhout V et al (2020) Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer. EJNMMI Res 10:14","journal-title":"EJNMMI Res"},{"key":"286_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13550-024-01097-3","volume":"14","author":"CE Popescu","year":"2024","unstructured":"Popescu CE, Zhang B, Sartoretti T et al (2024) Evaluating the biodistribution for [(68)Ga]Ga-PSMA-11 and [(18)F]F-PSMA-1007 PET\/CT with an inter- and intrapatient based analysis. EJNMMI Res 14:36","journal-title":"EJNMMI Res"},{"key":"286_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41391-020-00292-2","volume":"24","author":"BM Priv\u00e9","year":"2021","unstructured":"Priv\u00e9 BM, Isra\u00ebl B, Schilham MGM et al (2021) Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis 24:423\u2013430","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"286_CR16","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D et al (2024) The homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging 51:3753\u20133764","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"286_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00259-020-04846-3","volume":"48","author":"C Uprimny","year":"2021","unstructured":"Uprimny C, Bayerschmidt S, Kroiss AS et al (2021) Impact of forced diuresis with Furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [(68)Ga]Ga-PSMA-11-PET\/CT in the evaluation of prostate cancer patients. Eur J Nucl Med Mol Imaging 48:123\u2013133","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"286_CR15","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1007\/s00259-022-05745-5","volume":"49","author":"B Vollnberg","year":"2022","unstructured":"Vollnberg B, Alberts I, Genitsch V et al (2022) Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET\/CT for prostate cancer-a single-centre experience of PET-guided biopsies. Eur J Nucl Med Mol Imaging 49:3910\u20133916","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"286_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11864-024-01181-9","volume":"25","author":"AB Weiner","year":"2024","unstructured":"Weiner AB, Agrawal R, Valle LF et al (2024) Impact of PSMA PET on prostate cancer management. Curr Treat Options Oncol 25:191\u2013205","journal-title":"Curr Treat Options Oncol"},{"key":"286_CR5","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/MNM.0000000000001007","volume":"40","author":"M Wondergem","year":"2019","unstructured":"Wondergem M, van der Zant FM, Rafimanesh-Sadr L et al (2019) Effect of forced diuresis during 18F-DCFPyL PET\/CT in patients with prostate cancer: activity in ureters, kidneys and bladder and occurrence of halo artefacts around kidneys and bladder. Nucl Med Commun 40:652\u2013656","journal-title":"Nucl Med Commun"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00286-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-026-00286-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00286-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:02:04Z","timestamp":1770937324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41824-026-00286-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1186\/s41824-026-00286-8","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients included in this manuscript signed a written informed consent form allowing anonymized evaluation and publication of their data. This evaluation was approved by the ethics committee of the University of Bern (KEK-Nr.2020\u2009\u2212\u200901162).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"KK: Speaking fees & travel stipend, Novartis Pharma Schweiz AG, Rotkreuz, Switzerland; PKC: no conflicts of interest, ILA: speaking fees from Novartis, Canada, AAO: honoria as a member of an advisory board of Novartis, AOR: no relevant conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"5"}}